Therapeutic divergence phenomenon of gefitinib in the treatment of nonsmall cell lung cancer
ZHANG Xia
SONG Fei-xiang
RUAN Xin-jian
LI Hong-ying
JIA Zhi-ling
YU Zhong-he
Abstract：Objective: To investigate the characteristics and strategy of the therapeutic divergence phenom-enon of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TKI), in the treatment ot nonsmall cell lung cancer (NSCLC). Methods: The authors analyzed the therapeutic divergence phenomenon in 4 pattens with NSCLC during treatment with gefitinib at Bejing Military Area General Hospital between 2006 and 2008. Results: The therapeutic divergence phenomenon occurred in patients with NSCLC, who were complicated with bone and brain metastases and treated with gefitinib. In one of the four patients, NSCLC was controlled, bul the disease recurred in the bone and gefitinib therapy continued, and the clinical benefit continued. Conclusion: The therapeutic divergence phenomenon is common in the patients with NSCLC treated with gefitinib. The available evaluation criterion for oncotheropeutic effect may be not completely suitable to biologically targeted therapy. The intrinsic mechanism of this phenomenon needs further research for the formulate evaluation criterion and therapeutic strategy suitable for the biologically targeted therapy.
Keywords：non-small cell lung cancertyrosine kinase inhibitortherapeutic divergence phenomenongefitinibtargeted therapy
Publication Date：2009-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：5( 1320-1323,1327 )